The summaries are free for public
use. The Chronic Liver Disease
Foundation will continue to add and
archive summaries of articles deemed
relevant to CLDF by the Board of
Trustees and its Advisors.
Abstract Details
Hepatotoxicity and Potential Drug Interaction with Ledipasvir/Sofosbuvir In HIV/HCV Infected Patients
Tseng A1, Wong DK1. J Hepatol. 2016 May 19. pii: S0168-8278(16)30201-X. doi: 10.1016/j.jhep.2016.05.015. [Epub ahead of print]
Author information
1Immunodeficiency Clinic, University Health Network, Toronto, Canada. Electronic address: alice.tseng@uhn.ca.
Abstract
A rare side effect of ledipasvir/sofosbuvir is liver injury, which occurs within 2-6 weeks of starting treatment. Total and direct bilirubin values are greatly increased, and worsening of liver function may occur; symptoms are usually reversible when treatment is stopped. An interaction with lopinavir/ritonavir may contribute to this adverse effect.